Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma

(2019) Timothy A Brighton et al.   CLINICAL CANCER RESEARCH

Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression

(2018) Carlos Fernández de Larrea et al.   LEUKEMIA

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria

(2018) Arjun Lakshman et al.   Blood Cancer Journal

CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

(2017) Arnab Ghosh et al.   LEUKEMIA & LYMPHOMA

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

(2016) Christopher McCudden et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

(2016) Pamela L. Clemens et al.   CLINICAL PHARMACOKINETICS

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

(2016) Niels W. C. J. van de Donk et al.   IMMUNOLOGICAL REVIEWS

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

(2016) Marije B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

(2016) María-Victoria Mateos et al.   LANCET ONCOLOGY

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

(2016) P Ravi et al.   Blood Cancer Journal

Smoldering multiple myeloma

(2015) S. V. Rajkumar et al.   BLOOD

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

(2015) Marije B Overdijk et al.   mAbs

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

(2015) Neha Korde et al.   JAMA Oncology

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Smoldering multiple myeloma requiring treatment: time for a new definition?

(2013) A. Dispenzieri et al.   BLOOD

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

(2007) A. Dispenzieri et al.   BLOOD